Troriluzole, an investigational oral symptomatic treatment developed by Biohaven for Alzheimer’s disease, did not work better than a…
Articles by Joana Carvalho, PhD
Axsome Therapeutics has launched a Phase 3 trial that will assess the safety and efficacy of AXS-05,…
Donanemab (LY3002813), Eli Lilly’s experimental antibody-based immunotherapy, slowed cognitive and functional decline in patients at the earlier stages of…
BXCL501, BioXcel Therapeutics’ experimental therapy for the treatment of agitation associated with dementia, was found to be…
Most of the mild to moderate Alzheimer’s patients enrolled in the atuzaginstat (COR388) Phase 2/3 trial show evidence of systemic infection…
The European Medicines Agency (EMA) has agreed to review Biogen and Eisai’s application requesting the approval of aducanumab…
Treatment with sumifilam significantly lowered the levels of multiple biomarkers of disease activity, neurodegeneration, and inflammation in…
Biogen and Eisai have submitted a biologics license application (BLA) to the U.S. Food and Drug…
The Bacillus Calmette-Guérin (BCG) vaccine, which provides protection against tuberculosis, can reduce the incidence of Alzheimer’s disease…
Ionis Pharmaceuticals has licensed IONIS-MAPTRx (BIIB080), its investigational antisense therapy for the treatment of Alzheimer’s disease,…